Collaborative Arrangements (Tables)

3 Months Ended

Sep. 30, 2013

Collaborative Arrangements

Collaborator revenues

During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the CFFT collaboration:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
	(in thousands)				(in thousands)
Collaborative revenues attributable to the CFFT collaboration	$	3,515	$	4,315	$	11,318	$	12,772

During the three and nine months ended September 30, 2013 and 2012, the Company recognized the following revenues attributable to the Janssen collaboration:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2013		2012			2013		2012
	(in thousands)					(in thousands)
Royalty revenues (INCIVO)	$	20,994	$	19,957		$	104,108	$	80,811
Collaborative revenues:
Amortized portion of up-front payment	$	3,107	$	3,107		$	9,321	$	9,321
Net reimbursement (payment) for telaprevir development costs	1,413		(503		)	1,422		(2,569		)
Reimbursement for manufacturing services	—		—			10,299		4,449
Total collaborative revenues attributable to the Janssen collaboration	$	4,520	$	2,604		$	21,042	$	11,201
Total revenues attributable to the Janssen collaboration	$	25,514	$	22,561		$	125,150	$	92,012

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss (income) attributable to noncontrolling interest (Alios) for the three and nine months ended September 30, 2013 and 2012 is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
	(in thousands)						(in thousands)
Loss before provision for (benefit from) income taxes	$	9,056		$	5,090		$	21,177		$	14,581
Decrease (increase) in fair value of contingent milestone and royalty payments	(1,220		)	(57,560		)	1,600			(112,760		)
Provision for (benefit from) income taxes	(3,306		)	21,394			(9,089		)	40,354
Net loss (income) attributable to noncontrolling interest (Alios)	$	4,530		$	(31,076	)	$	13,688		$	(57,825	)

Summary of Alios' items included in the Company's consolidated balance sheets

The following table summarizes items related to Alios included in the Company’s condensed consolidated balance sheets:

	As of September 30, 2013		As of December 31, 2012
	(in thousands)
Restricted cash and cash equivalents (Alios)	$	51,059	$	69,983
Prepaid expenses and other current assets	8,821		672
Property and equipment, net	1,374		1,728
Intangible assets	250,600		250,600
Goodwill	4,890		4,890
Other assets	153		861
Accounts payable	1,251		1,054
Accrued expenses	6,689		6,099
Deferred tax liability	150,203		152,781
Other liabilities, excluding current portion	873		1,625
Redeemable noncontrolling interest (Alios)	39,624		38,530
Noncontrolling interest (Alios)	182,168		196,672